Tag: NASDAQ:MGNX

January 28, 2019

MacroGenics Announces Removal of Partial Clinical Hold on MGD009 Program by FDA

MacroGenics (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer,...
December 24, 2018

Pharma Outlook 2019: Drug Pricing Dialogue Continues

During this challenging time in healthcare news, our pharma outlook aims to help investors steer through the industry.